钆螯合物给药与T1加权磁共振成像采集之间延迟增加会增大脑肿瘤患者的强化肿瘤体积和T1信号强度
这项前瞻性重测研究分析了55例组织学确诊的强化性脑实质内肿瘤患者,在常规随访中连续进行两次3 T MRI扫描(间隔1分钟休息),仅第一次ceT1-w采集前注射大环类钆螯合物对比剂,中位延迟第一次为6.72分钟、第二次为16.27分钟。结果显示第二次采集的强化肿瘤体积显著增大(中位+32% [1.2 cm]),强化肿瘤直径增加10%(+0.3 cm),坏死和非强化肿瘤体积显著减小,早期和晚期强化区域的相对ceT1-w强度分别增加5.8%和27.3%。作者认为强化肿瘤体积和强度的最大范围可能在注射对比剂后4至8分钟时间窗之后继续增加,可能影响进展期或复发疾病的诊断。
要点
- 延迟ceT1-w采集至中位16.27分钟时,强化肿瘤体积较中位6.72分钟时增大32%(+1.2 cm),直径增加10%(+0.3 cm)。
- 延迟采集时坏死体积减小24%,非强化肿瘤体积减小2%,早期和晚期强化区T1强度分别增加5.8%和27.3%。
- 强化体积和强度的增加与对比剂注射至ceT1-w采集的间隔时间呈函数关系(线性混合效应模型P<0.01)。
核心结论
- 研究表明强化肿瘤体积和强度的最大范围可能在注射对比剂后4至8分钟时间窗之后继续增加,可能影响进展期或复发疾病的诊断,因为晚期强化复发疾病在标准随访MRI上可能无法被明确检测。
研究设计与样本
- 前瞻性重测研究,纳入55例组织学确诊的强化性脑实质内肿瘤患者,在常规随访中连续进行两次3 T MRI扫描(间隔1分钟休息),采集ceT1-w、T2和FLAIR序列;大环类钆螯合物对比剂仅在第一次ceT1-w采集前注射;第一次ceT1-w采集中位延迟6.72分钟(IQR 6.53-6.92),第二次中位延迟16.27分钟(IQR 15.49-17.26);采用半自动肿瘤分割分别评估强化(CE)、坏死(NEC)和非强化(NE)肿瘤。
关键影像表现/征象
- 第二次采集时半自动分割的强化肿瘤体积显著增大,中位+32%(1.2 cm),IQR 16%-62%,P<0.01,对应强化肿瘤直径增加10%(+0.3 cm)。
- 第二次采集时坏死肿瘤体积显著减小,中位-24%(IQR -36%至-54%),P<0.01。
- 第二次采集时非强化肿瘤体积显著减小,中位-2%(IQR -1%至-3%),P=0.02。
- Bland-Altman图证实第二次ceT1-w采集存在强化体积偏高、坏死体积偏低的 proportional bias。
- 第二次采集时早期强化区(第一次扫描已强化区域)和晚期强化区(第二次扫描新强化区域)的相对ceT1-w强度分别增加5.8%和27.3%(P<0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim of this study was to evaluate the impact of delayed T1-weighted (T1-w) MRI acquisition after gadolinium chelate administration on brain tumor volumes and T1-w intensities.
MATERIALS AND METHODS: Fifty-five patients with histologically confirmed, contrast-enhancing intra-axial brain tumors were analyzed in this prospective test-retest study. Patients underwent 2 consecutive 3 T MRI scans (separated by a 1-minute break) during routine follow-up with contrast-enhanced T1 (ceT1-w), T2, and FLAIR acquisition. Macrocyclic gadolinium chelate-based contrast agent was only administered before the first ceT1-w acquisition; median latency to ceT1-w acquisition was 6.72 minutes (IQR, 6.53-6.92) in the first and 16.27 minutes (IQR, 15.49-17.26) in the second scan. Changes in tumor volumes and relative ceT1-w intensities between the 2 acquisitions were quantitatively assessed following semiautomated tumor segmentation (separately for contrast-enhancement [CE], necrosis [NEC], and nonenhancing [NE] tumor).
RESULTS: Semiautomatically segmented CE tumor volumes were significantly larger in the second acquisition (median +32% [1.2 cm]; IQR, 16%-62%; P < 0.01), which corresponded to a 10% increase in CE tumor diameter (+0.3 cm). Contrarily, NEC and NE tumor volumes were significantly smaller (median -24% [IQR, -36% to -54%], P < 0.01 for NEC and -2% [IQR, -1% to -3%], P = 0.02 for NE tumor). Bland-Altman plots confirmed a proportional bias toward higher CE and lower NEC volumes for the second ceT1-w acquisition. Relative ceT1-w intensities for both early- (regions already enhancing in the first scan) and late-enhancing (newly enhancing regions in the second scan) tumor were significantly increased in the second acquisition (by 5.8% and 27.3% [P < 0.01, respectively]). Linear-mixed effects modeling confirmed that the increase in CE volumes and CE intensities is a function of the interval between contrast agent injection and ceT1-w acquisition (P < 0.01 each).
CONCLUSIONS: Our study indicates that the maximum extent of CE tumor volumes and intensities may increase beyond the time frame of 4 to 8 minutes after contrast agent injection and potentially affects the diagnosis of progressive or recurrent disease because late-enhancing recurrent disease might not be unequivocally detected on standard follow-up MRI.
引用
- Piechotta PL, Bonekamp D, Sill M, et al. Increased Delay Between Gadolinium Chelate Administration and T1-Weighted Magnetic Resonance Imaging Acquisition Increases Contrast-Enhancing Tumor Volumes and T1 Intensities in Brain Tumor Patients. Invest Radiol. 2018. PMID: 29200014. doi:10.1097/RLI.0000000000000432
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。